All NewsBio/Pharma News
All PublicationsPharmTechPharmTech Europe
MarketplaceICH Q9 Revision: A Comprehensive Resource on Quality Risk ManagementPeer-Reviewed ResearchPharmTech ProductsPharma InsightsSponsored PodcastsSponsored VideosSponsored eBooksWhitepapers
Webcasts
All VideosAsk the ExpertBehind The HeadlinesBuy, Sell, HoldDrug Digest VideosDrug Solutions PodcastPeer ExchangeSexy ScienceTech Talk
Conference CoverageConference ListingEvents
Subscribe
AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Deals, Development and Manufacturing
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
Global Perspectives
Intellectual Property & Patents
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
Mergers and Acquisitions
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality SystemsQuality Systems
Spotlight -
  • Analytics
  • Dosage Forms
  • Drug Development
  • Manufacturing
  • Outsourcing
  • Quality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

AnalyticsAnalyticsAnalytics
Data and Artificial Intelligence
Deals, Development and Manufacturing
Dosage FormsDosage FormsDosage FormsDosage FormsDosage Forms
Drug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug DevelopmentDrug Development
Global Perspectives
Intellectual Property & Patents
ManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturingManufacturing
Mergers and Acquisitions
OutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcingOutsourcing
Quality SystemsQuality SystemsQuality SystemsQuality SystemsQuality Systems
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Webcasts
    • Subscribe
Advertisement

Therapeutic Delivery for Brain-Related Conditions

June 12, 2024
By Joe Petroziello
News
Article

At BIO 2024 in San Diego, John Dunlop, PhD, chief scientific officer at Aliada Therapeutics, sat down for an interview with Pharmaceutical Technology to discuss the firm’s MODEL platform and its potential impact on therapeutic delivery for brain-related conditions.

John Dunlop, PhD, chief scientific officer at Aliada Therapeutics.

John Dunlop, PhD, chief scientific officer at Aliada Therapeutics.

[Editor’s note: This interview has been lightly edited for brevity and clarity.]

At BIO 2024 in San Diego, John Dunlop, PhD, chief scientific officer at Aliada Therapeutics, sat down for an interview with Pharmaceutical Technology® to discuss the firm’s MODELTM platform and its potential impact on therapeutic delivery for brain-related conditions. The platform leverages highly optimized protein domains that target the transferrin receptor (TfR) and CD98 receptor, which are key for transporting agents across the blood-brain barrier.

PharmTech: Can you tell us about Aliada’s MODEL platform and discuss the science driving this novel approach?

Dunlop: Starting with the name, the term MODEL stands for Modular Delivery, which I think speaks to the breadth and flexibility of our platform. We have several design tools with the key components of the MODEL platform being highly optimized protein domains that bind to either the transferrin receptor or the CD98 receptor. These are both highly expressed on brain endothelial cells and are responsible for transporting physiological agents across the blood-brain barrier: transferrin via TfR and CD98 as part of a heterodimer of the large amino acid transporter. We take advantage of those by engineering highly optimized TfR or CD98 binders that we can then use to attach to different types of cargo. The cargo can be therapeutic antibodies, or enzymes for enzyme replacement therapy, for example (See Figures 1-2).

Figure 1. MODEL leverages the transferrin and CD98 receptors (TfR and CD98) with engineered protein domains attached to cargoes that can cross the blood-brain barrier via transcytosis. Image courtesy of Aliada Therapeutics.

Figure 1. MODEL leverages the transferrin and CD98 receptors (TfR and CD98) with engineered protein domains attached to cargoes that can cross the blood-brain barrier via transcytosis. Image courtesy of Aliada Therapeutics.

Figure 2. Because TfR and CD98 are expressed on resident cells inside the brain as well as the epithelial cells of the BBB, MODEL can also mediate cargo uptake by neurons, microglia and macrophages through a process known as receptor-mediated endocytosis. Image courtesy of Aliada Therapeutics.

Figure 2. Because TfR and CD98 are expressed on resident cells inside the brain as well as the epithelial cells of the BBB, MODEL can also mediate cargo uptake by neurons, microglia and macrophages through a process known as receptor-mediated endocytosis. Image courtesy of Aliada Therapeutics.

We are also placing a major strategic focus on oligonucleotide therapeutics. The current standard of care is to deliver these through an intrathecal route of administration. Our premise is that we can generate antibody-oligonucleotide conjugate scaffolds using the TfR or CD98 delivery modules, which allows for the potential of a peripheral route of administration via IV—maybe even subcutaneous in the future—and achieve target knockdown of a particular gene of interest in the brain. We are solving one of the big challenges with this direct intrathecal delivery, which is very invasive and associated with numerous toxicities.

The MODEL platform contains a number of different components. The workhorse delivery module is a single chain Fv, a component of the antibody that typically binds to the antigen. We have stabilized that through proprietary stapling technology. Those protein domains are typically inherently very unstable, so that is one of our true differentiators. The fact that it is just a single chain Fv gives us the ability to attach it to different types of cargo in a very flexible way. Finally, there are several different antibodies we utilize like scaffolds, one of which we call the mono IgG. It has a single Fab arm that is addressing either TfR or CD98. The importance is that with the Fc retained there, you can use it as “real estate” where you can conjugate things like oligonucleotides. We are starting to do a lot more work in that area to really build that up.

PharmTech: What are the main areas of focus as Aliada develops its MODEL platform?

Dunlop: The first is reducing the platform to practice, particularly around RNA therapeutics, and that'll be both in the field of siRNA as well as antisense oligonucleotides.

And then the other primary focus is our lead program [ALIA-1758], which is an antibody-based therapeutic that is enabled with our transferrin single-chain Fv delivery module, developed for early Alzheimer's disease. It is an amyloid beta (Aβ) targeted antibody that targets the pyroglutamate forms of Aβ. These are highly aggregate-prone forms of Aβ and are very much expressed in the plaques in the human brain. It is the same epitope that is targeted by a molecule called donanemab which is in development by Eli Lilly.

We have engineered some important attributes that I believe will differentiate us from donanemab. In terms of the pyroglutamate binders, we have a significantly increased affinity for pyroglutamate compared to donanemab. Additionally, we have configured the molecule with our single-chain Fv transferrin brain shuttle, so we get much more of the antibody delivered into the brain. With these two factors, we believe we could have a once-monthly, subcutaneous administration at a very low dosage level. Other agents in the field are IV administration, so you need to go into an infusion center and spend time there. We think we can really bring what could be a best-in-class asset to Alzheimer's patients.

The exciting part there is that we are imminently about to start our clinical trial. It will be a single ascending dose study in healthy volunteers to understand safety, tolerability, and initial pharmacokinetics. That will set us up ultimately to then do a multiple ascending dose study in Alzheimer's patients. It will be very exciting for us to be able to say we are a clinical-stage company, and that's going to happen very soon.

PharmTech: Are you excited about the seemingly accelerating progress in the Alzheimer’s disease field in recent years?

Dunlop: I think there has been just tremendous progress in the Alzheimer’s disease space. Biomarkers now really make us very confident that subjects coming into trials already have evidence of amyloid pathology in the brain, because we can look at it through PET imaging and we can measure different beta-amyloid and tau species in the blood that are also correlated with those PET images. When you think back to the initial trials of some of the initial Aβ antibodies almost 30 years ago, about a third of the subjects who were enrolled in those trials didn’t actually have amyloid pathology in their brain, which we learned when they passed away. They had some other type of dementia, instead. This factor was diluting the potential to see a signal in a clinical trial. Now we can very definitively recruit subjects with Alzheimer’s disease, and we are very biomarker-enabled to track the progress of our therapeutics. So, we’re very excited to be starting our clinical program very soon.

Recent Videos
AAPS National Biotechnology Conference 2025: High-Concentration Biologics
AAPS National Biotechnology Conference 2025: High-Concentration Biologics
Industry Outlook 2025: The Future of Technology in the Biopharma Industry
Industry Outlook 2025: The Future of Technology in the Biopharma Industry
AAPS National Biotechnology Conference 2025: AAV Vector Production
AAPS National Biotechnology Conference 2025: AAV Vector Production
Industry Outlook 2025: European Geopolitical Impact on Pharma
Industry Outlook 2025: European Geopolitical Impact on Pharma
Behind the Headlines Episode 16: NIH Funding, Re-Shoring, Tariffs, and Cell and Gene Therapies
Behind the Headlines Episode 16: NIH Funding, Re-Shoring, Tariffs, and Cell and Gene Therapies
Industry Outlook 2025: Political Implications for Pharma
Industry Outlook 2025: Political Implications for Pharma
Industry Outlook 2025: Mergers, Acquisitions, and Funding
Industry Outlook 2025: Mergers, Acquisitions, and Funding
Industry Outlook 2025: The Impact of Politics on Pharma
Industry Outlook 2025: The Impact of Politics on Pharma
Behind the Headlines Episode 15–Neuroscience, Weight-Loss Drugs, and Tariffs
Behind the Headlines Episode 15–Neuroscience, Weight-Loss Drugs, and Tariffs
Industry Outlook 2025: Technology as a Supporting Element
Industry Outlook 2025: Technology as a Supporting Element
Related Content
Advertisement

Pharmacy, hands and prescription medicine for customer with paper bag for healthcare, drugs and pharmaceutical. Closeup of a pharmacist or medical worker with person in drugstore for retail service | Image Credit: © Azee Jacobs/peopleimages.com - stock.adobe.com

Trump Issues Executive Order Aimed at Reducing Prescription Drug Prices for US Patients

Patrick Lavery
May 13th 2025
Article

According to the White House, the order builds on actions taken in the president’s first term to reduce price disparities domestically.


Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol
April 30th 2024
Podcast

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.


Insulin Vial Trapped in Ice for Diabetic Challenges | Image Credit: ©Nisit – stock.adobe.com

Parenteral Formulation: Deciding When to Go Frozen or Freeze-Dried

Cynthia A. Challener
May 8th 2025
Article

Scientific, economic, and practical factors should be considered when choosing between the frozen state and lyophilization.


Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

March 26th 2024
Podcast

In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.


Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

GSK Previews Oral and Poster Abstracts for ATS International Congress

Patrick Lavery
May 5th 2025
Article

The company is presenting data related to its medications designed to advance the prevention and treatment of asthma and COPD.


Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

Cancer Research and Treatment Center Planned for London

Susan Haigney
May 1st 2025
Article

Aviva Capital Partners and developer Socius are investing £1 billion to develop a cancer research and treatment center in Sutton, London.

Related Content
Formulation and Drug Delivery
|
Drug Development
|
Latest Conference
Advertisement

Pharmacy, hands and prescription medicine for customer with paper bag for healthcare, drugs and pharmaceutical. Closeup of a pharmacist or medical worker with person in drugstore for retail service | Image Credit: © Azee Jacobs/peopleimages.com - stock.adobe.com

Trump Issues Executive Order Aimed at Reducing Prescription Drug Prices for US Patients

Patrick Lavery
May 13th 2025
Article

According to the White House, the order builds on actions taken in the president’s first term to reduce price disparities domestically.


Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol
April 30th 2024
Podcast

In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.


Insulin Vial Trapped in Ice for Diabetic Challenges | Image Credit: ©Nisit – stock.adobe.com

Parenteral Formulation: Deciding When to Go Frozen or Freeze-Dried

Cynthia A. Challener
May 8th 2025
Article

Scientific, economic, and practical factors should be considered when choosing between the frozen state and lyophilization.


Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development

March 26th 2024
Podcast

In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.


Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

GSK Previews Oral and Poster Abstracts for ATS International Congress

Patrick Lavery
May 5th 2025
Article

The company is presenting data related to its medications designed to advance the prevention and treatment of asthma and COPD.


Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

Cancer Research and Treatment Center Planned for London

Susan Haigney
May 1st 2025
Article

Aviva Capital Partners and developer Socius are investing £1 billion to develop a cancer research and treatment center in Sutton, London.

Advertisement
Advertisement
Advertisement
x
About Us
Advertise
Contact Us
Editorial Info
Editorial Advisory Board
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.